Importance of cost-effectiveness and value in cancer care and healthcare policy. Review uri icon

Overview

abstract

  • The cost of cancer care has increased by five fold over the last three decades. As our healthcare system shifts from volume to value, greater scrutiny of interventions with clinical equipoise is required. Traditionally, QALYs and ICER have served as surrogate markers for value. However, this approach fails to incorporate all stakeholders' viewpoints. Prostate cancer, low risk DCIS, and thyroid cancer are used as a framework to discuss value and cost-effectiveness. J. Surg. Oncol. 2016;114:275-280. © 2016 Wiley Periodicals, Inc.

publication date

  • June 22, 2016

Research

keywords

  • Breast Neoplasms
  • Health Policy
  • Prostatic Neoplasms
  • Thyroid Neoplasms

Identity

PubMed Central ID

  • PMC5048466

Scopus Document Identifier

  • 84983364662

Digital Object Identifier (DOI)

  • 10.1002/jso.24331

PubMed ID

  • 27334052

Additional Document Info

volume

  • 114

issue

  • 3